Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial
Karin Ried, Taufiq Binjemain, Avni Sali
Cureus, doi:10.7759/cureus.19902
Background COVID-19 is a global pandemic. Treatment with hydroxychloroquine (HCQ), zinc, and azithromycin (AZM), also known as the Zelenko protocol, and treatment with intravenous (IV) vitamin C (IVC) have shown encouraging results in a large number of trials worldwide. In addition, vitamin D levels are an important indicator of the severity of symptoms in patients with COVID-19.
Objectives Our multicenter, randomized, open-label study aimed to assess the effectiveness of HCQ, AZM, and zinc with or without IVC in hospitalized patients with COVID-19 in reducing symptom severity and duration and preventing death.
Methods Hospitalized patients with COVID-19 in seven participating hospitals in Turkey were screened for eligibility and randomly allocated to receive either HCQ, AZM, and zinc (group 1) or HCQ, AZM, zinc plus IV vitamin C treatment (group 2) for 14 days. The patients also received nontherapeutic levels of vitamin D3. The trial is registered on the Australian and New Zealand Clinical Trial Registry ACTRN12620000557932 and has been approved by the Australian Therapeutic Goods Administration (TGA).
Results A total of 237 hospitalized patients with COVID-19 aged 22-99 years (mean: 63.3 ± 15.7 years) were enrolled in the study. Almost all patients were vitamin D deficient (97%), 55% were severely vitamin D deficient (<25 nmol/L) and 42% were vitamin D deficient (<50 nmol/L); 3% had insufficient vitamin D levels (<75 nmol/L), and none had optimal vitamin D levels. Of the patients, 73% had comorbidities, including diabetes (35%), heart disease (36%), and lung disease (34%). All but one patient (99.6%; n = 236/237) treated with HCQ, AZM, and zinc with or without high-dose IV vitamin C (IVC) fully recovered. Additional IVC therapy contributed significantly to a quicker recovery (15 days versus 45 days until discharge; p = 0.0069). Side effects such as diarrhea, nausea, and vomiting, reported by 15%-27% of the patients, were mild to moderate and transient. No cardiac side effects were observed. Low vitamin D levels were significantly correlated with a higher probability of admission to the intensive care unit (ICU) and longer hospital stay.
References
Andreani, Bideau, Duflot, In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microb Pathog,
doi:10.1016/j.micpath.2020.104228
Baradaran, Ebrahimzadeh, Baradaran, Kachooei, Prevalence of comorbidities in COVID-19 patients: a systematic review and meta-analysis, Arch Bone Jt Surg,
doi:10.22038/abjs.2020.47754.2346
Benskin, A basic review of the preliminary evidence that COVID-19 risk and severity is increased in vitamin D deficiency, Front Public Health,
doi:10.3389/fpubh.2020.00513
Borsche, Glauner, Jv, COVID-19 mortality risk correlates inversely with vitamin D3 status, and a mortality rate close to zero could theoretically be achieved at 50 ng/ml 25 (OH) D3: results of a systematic review and meta-analysis, Nutrients,
doi:10.1101/2021.09.22.21263977
Bosseboeuf, Aubry, Nhan, De Pina, Rolain et al., Azithromycin inhibits the replication of Zika virus, J Antivir Antiretrovir,
doi:10.4172/1948-5964.1000173
Cerullo, Negro, Parimbelli, The long history of vitamin C: from prevention of the common cold to potential aid in the treatment of COVID-19, Front Immunol,
doi:10.3389/fimmu.2020.574029
Derwand, Scholz, Zelenko, COVID-19 outpatients: early risk-stratified treatment with zinc plus lowdose hydroxychloroquine and azithromycin: a retrospective case series study, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.106214
Gautret, Lagier, Parola, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents,
doi:10.1016/j.ijantimicag.2020.105949
Hernández, Nan, Fernandez-Ayala, Vitamin D status in hospitalized patients with SARS-CoV-2 infection, J Clin Endocrinol Metab,
doi:10.1210/clinem/dgaa733
Huang, Wang, Tan, Liu, Ni, High-dose vitamin C intravenous infusion in the treatment of patients with COVID-19: a protocol for systematic review and meta-analysis, Medicine,
doi:10.1097/MD.0000000000025876
Mahmoodpoor, Shadvar, Sanaie, Hadipoor, Pourmoghaddam et al., Effect of vitamin C on mortality of critically ill patients with severe pneumonia in intensive care unit: a preliminary study, BMC Infect Dis,
doi:10.1186/s12879-021-06288-0
Martineau, Jolliffe, Hooper, Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data, BMJ,
doi:10.1136/bmj.i6583
Matin, Fouladi, Pahlevan, The sufficient vitamin D and albumin level have a protective effect on COVID-19 infection, Arch Microbiol,
doi:10.1007/s00203-021-02482-5
Merzon, Tworowski, Gorohovski, Vinker, Cohen et al., Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study, FEBS J,
doi:10.1111/febs.15495
Tanriverdi, Çörtük, Yildirim, Hydroxychloroquine plus azithromycin and early hospital admission are beneficial in COVID-19 patients: Turkish experience with real-life data, Turk J Med Sci,
doi:10.3906/sag-2005-82
Thomas, Patel, Bittel, Effect of high-dose zinc and ascorbic acid supplementation vs usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: the COVID A to Z randomized clinical trial, JAMA Netw Open,
doi:10.1001/jamanetworkopen.2021.0369
Travica, Ried, Bujnowski, Sali, Integrative health check reveals suboptimal levels in a number of vital biomarkers, Adv Integr Med,
doi:10.1016/j.aimed.2015.11.002
Velthuis, Van Den Worm, Sims, Baric, Snijder et al., Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture, PLoS Pathog,
doi:10.1371/journal.ppat.1001176
Xu, Baylink, Chen, The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19, J Transl Med,
doi:10.1186/s12967-020-02488-5
Yang, Shen, Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19, Int J Biol Sci,
doi:10.7150/ijbs.45498
Yildiz, Senel, Kavurgaci, Ozturk, Ozturk, The prognostic significance of vitamin D deficiency in patients with COVID-19 pneumonia, Bratisl Lek Listy,
doi:10.4149/BLL_2021_119
Zhao, Liu, Liu, High dose intravenous vitamin C for preventing the disease aggravation of moderate COVID-19 pneumonia. a retrospective propensity matched before-after study, Front Pharmacol,
doi:10.3389/fphar.2021.638556